Albert Bourla, the Chairman and CEO of Pfizer Inc, has reported an acquisition of 20 phantom stock units, a move that underscores his commitment to the company. This transaction occurred on October 15, 2026, and was disclosed in a recent SEC filing.
Pfizer Inc, a major player in the pharmaceutical industry, is known for its development of innovative drugs and vaccines. The company is listed under the SIC code for Pharmaceutical Preparations [2834]. It has been actively involved in addressing global health challenges, particularly during the COVID-19 pandemic.
According to the filing, Bourla acquired the phantom stock units at a price of $29.44 each. Following this transaction, he now owns a total of 783,997 shares. The filing states, "Each unit represents one phantom share of common stock," indicating that these units are settled in cash after Bourla's separation from service.
This acquisition may affect various stakeholders, including investors and employees, as it reflects Bourla's ongoing confidence in Pfizer's strategic direction. Stability in leadership is often seen as a positive sign in the pharmaceutical sector, which is currently navigating numerous challenges.
The filing does not specify what happens next regarding Bourla's ownership or any future transactions.
Albert Bourla's acquisition of phantom stock units is part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, which allows for cash settlement following his separation from service. This plan provides flexibility, as Bourla may also transfer the units into an alternative investment account at any time.
The SEC filing indicates that Bourla's ownership of shares is classified as direct ownership, demonstrating his personal stake in the company. This reflects a broader trend in corporate governance where executives are encouraged to align their financial interests with those of shareholders.
Additionally, the filing does not provide any details regarding Bourla's future plans for his stock holdings or any potential changes in his role within Pfizer Inc. It remains unclear how this acquisition might influence his decision-making or strategic direction for the company moving forward.